Study on the intracellular Network of TBX3
TBX3细胞内网络的研究
基本信息
- 批准号:7849304
- 负责人:
- 金额:$ 5.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-08-01 至 2011-05-31
- 项目状态:已结题
- 来源:
- 关键词:AmericanBasic Research Breast CancerBindingBinding SitesBiologicalBiological AssayBiological MarkersBoxingBreast Cancer CellCDKN2A geneCancer cell lineCellsChromatinChromatin StructureClinicalDevelopmentEmbryoFibroblastsGene ExpressionGene FamilyGene TargetingGenesGeneticGenetic TranscriptionGlutathione S-TransferaseGoalsGrowthHDAC1 geneHistone DeacetylaseHumanImmunohistochemistryIn Situ HybridizationIn VitroIndividualKnock-outKnockout MiceLeadLigationLuciferasesMalignant NeoplasmsMammary glandMediatingMolecularMolecular BiologyMusMutationNormal tissue morphologyOligonucleotidesOutcomePathogenesisPathway interactionsPatientsPhysiologicalPlayPrecipitationPromoter RegionsProteinsRecruitment ActivityResearchResearch PersonnelRoleSensitivity and SpecificitySeriesSerumSyndromeTP53 geneTechniquesTestingTissuesTransfectionTumor Suppressor GenesTumor Suppressor ProteinsWomanbasebreast cancer diagnosischromatin immunoprecipitationclinical applicationcofactorexperiencegenome-widehuman HDAC1 proteinhuman diseasein vitro Assayin vivoinhibitor/antagonistmalignant breast neoplasmmammary gland developmentnew therapeutic targetnoveloverexpressionprogramspromoterresearch studytooltranscription factortumor growth
项目摘要
Although breast cancer is one of the most common malignancies in American women, the genetic
mechanisms responsible for its pathogenesis and clinical course remain largely unclear. TBX3 is a T-box
transcription factor that may play a role in breast cancer and has not been previously investigated. Mutations of
TBX3 in humans and mice show the clinical features of hypoplastic or absence of the mammary gland. Our
earlier studies demonstrate that TBX3 is overexpressed in breast cancer cell lines, and can immortalize and
transform mouse embryo fibroblast cells. TBX3 can also inhibit the expression of the p14ARF gene, a tumor
suppressor and an inhibitor of MDM2-mediated degradation of p53. Therefore, overexpression of TBX3
decreases the stability of p53. Most recently, TBX3 was found to be elevated in serum of the patients with breast
cancer. Collectively, these findings suggest that TBX3 plays an important role in breast cancer. In this proposal,
we show that TBX3 interacts with histone deacetylase (HDAC)1, 2 and 5. Our central hypothesis is that TBX3
overexpression is associated with breast cancer and that TBX3 recruits HDACs to the p14ARF promoter and
inhibits p14ARF tumor suppressor expression causing breast cancer.
Aim 1, we will examine whether TBX3 is overexpressed in primary breast cancer tissues. Expression levels
of TBX3 will be correlated with clinical outcomes and other established biomarkers. We anticipate that TBX3 could
be a novel biomarker for breast cancer. TBX3 is mechanistically implicated in tumor growth, presumably by
inhibiting the expression of p14ARF tumor suppressor gene. Although TBX3 has been characterized as a
transcriptional represser, the mechanism by which TBX3 represses gene expression is still unknown. Our
preliminary results show that TBX3 interacts with HDACs and that the interaction is physiologically important. For
Aim 2, we hypothesize that TBX3 recruits HDACs to p14ARF promoter and represses p14ARF tumor suppressor
gene expression. We will test the interaction between TBX3 and HDACs by a series of in vivo and in vitro assays,
including immunohistochemical analysis, Glutathione-S-transferase (GST) pulldown assay and chromatin
immunoprecipitation (CHIP). Physiological significance of the TBX3-HDAC interaction will be further investigated
in breast cancer cells and with the p14ARF promoter. In Aim 3, we propose to identify the TBX3 direct targets via
chromatin immunoprecipitation-guided ligation selection (CHIP-GLAS). The CHIP-GLAS assay combines
chromatin precipitation and microarray, which could be used to identify 20,000 promoter DNA/transcription factor
interactions in one experiment with high sensitivity and specificity. Using this approach, we found that TBX3 binds
to more than 600 promoters. We will verify those target genes involved in breast cancer and mammary gland
development using various in vivo and in vitro assays.
An important feature of the proposed research is translational for the development of a novel biomarker for
breast cancer and basic biological information to clinical application will be optimized. Elucidation of the TBX3-
HDAC interaction will deepen our understanding of the functions of TBX3 and may also lead to the identification of
a novel therapeutic target for breast cancer.
虽然乳腺癌是美国女性中最常见的恶性肿瘤之一,但遗传
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TAOSHENG HUANG其他文献
TAOSHENG HUANG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TAOSHENG HUANG', 18)}}的其他基金
SLC25A46 mutations cause optic atrophy, axonal neuropathy, and cerebellar neurodegeneration
SLC25A46 突变导致视神经萎缩、轴突神经病变和小脑神经变性
- 批准号:
9265469 - 财政年份:2016
- 资助金额:
$ 5.72万 - 项目类别: